Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ross

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Haematologica|July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
Pathology|April 24, 2022
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statementAnoop K Enjeti, Rishu Agarwal, Piers Blombery, et al.
Blood|September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Blood Advances|December 27, 2024
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER studyVikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, et al.
Blood Cancer Journal|April 9, 2023
Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patientsAhmad Alcheikh, Griffith B Perkins, Phillippa A Pucar, et al.
EMBO Reports|February 14, 2022
Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibodyDenis Tvorogov, Chloe A L Thompson-Peach, Johannes Foßelteder, et al.
Plos One|September 19, 2024
CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targetingKelly Lim, Winnie L Kan, Pramod C Nair, et al.
Pathology|March 6, 2021
Myeloid somatic mutation panel testing in myeloproliferative neoplasmsDavid M Ross, Candice Thomson, Nada Hamad, et al.
Leukemia|September 3, 2021
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Haematologica|July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
Pathology|April 24, 2022
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statementAnoop K Enjeti, Rishu Agarwal, Piers Blombery, et al.
Blood|September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Blood Advances|December 27, 2024
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER studyVikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, et al.
Blood Cancer Journal|April 9, 2023
Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patientsAhmad Alcheikh, Griffith B Perkins, Phillippa A Pucar, et al.
EMBO Reports|February 14, 2022
Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibodyDenis Tvorogov, Chloe A L Thompson-Peach, Johannes Foßelteder, et al.
Plos One|September 19, 2024
CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targetingKelly Lim, Winnie L Kan, Pramod C Nair, et al.
Pathology|March 6, 2021
Myeloid somatic mutation panel testing in myeloproliferative neoplasmsDavid M Ross, Candice Thomson, Nada Hamad, et al.
Leukemia|September 3, 2021
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
Pageof 13